/

Empresas

Or

No verificado

OrsoBio, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa

16/01/2026

Biotecnología

Farmacéutica

Salud

Medicina - Varios

Industria

OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases

Fuente

Editor

1.00

0

16/12/2025

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

OrsoBio Announces Positive Topline Phase 1b/2a Clinical Data for its Oral Mitochondrial Protonophore TLC-6740 in Combination with Tirzepatide

Fuente

Editor

1.00

0

04/11/2025

Salud

Biotecnología

Medicina - Varios

Farmacéutica

Eventos

Industria

OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 2025

Fuente

Editor

1.00

0

20/06/2025

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Eventos

Industria

OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association’s 85th Scientific Sessions

Fuente

Editor

1.00

0

15/10/2024

Industria

Salud

Medicina - Varios

Farmacéutica

Cardiología

Biotecnología

OrsoBio Announces Publication of Preclinical Data on Novel Approach for Regulating Metabolic Dysfunction and Reducing Inflammation and Fibrosis

Fuente

Editor

1.00

0

06/09/2024

Mercado laboral

Industria

Ciencia

Cardiología

Biotecnología

Farmacéutica

Salud

Medicina - Varios

OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0